Regenxbio is a pioneering brand in the field of gene therapy, dedicated to improving lives through the curative potential of this innovative treatment. With their cutting-edge NAV® Technology Platform, Regenxbio is revolutionizing gene therapy and envisioning a brighter future for patients suffering from common and rare diseases. Their focus lies in the retinal, metabolic, and neurodegenerative therapeutic areas.

Driven by their mission and values, Regenxbio is developing a robust pipeline of gene therapy candidates, including ABBV-RGX-314 for Retinal Diseases, RGX-202 for Duchenne, RGX-121 for MPS II (Hunter Syndrome), RGX-111 for MPS I, RGX-181 for CLN2 Disease, and RGX-381 for CLN2 Disease. Regenxbio's dedication to patients goes beyond their innovative therapies. They prioritize their culture, making it a top work environment as recognized by the Washington Post in 2021 and 2022.

Join their team and contribute to groundbreaking research that truly matters. Stay updated by subscribing to their program updates and witness the extraordinary advancements in gene therapy made by Regenxbio, a leader in the field